Active, not recruitingPhase 3NCT06558279
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
Studying Adult-onset myasthenia gravis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- argenx
- Intervention
- Efgartigimod PH20 SC(combination_product)
- Enrollment
- 141 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (30)
- HonorHealth Neurology - Bob Bové Neuroscience Institute, Scottsdale, Arizona, United States
- Loma Linda University Health, Loma Linda, California, United States
- USC Roski Eye Institute - Los Angeles, Los Angeles, California, United States
- University of California San Francisco, San Francisco, California, United States
- Neurology Offices of South Florida, Boca Raton, Florida, United States
- SFM Clinical Research, LLC, Boca Raton, Florida, United States
- Neurology Associates PA, Maitland, Florida, United States
- University of South Florida, Tampa, Florida, United States
- Northwestern Memorial Hospital, Chicago, Illinois, United States
- University of California Irvine, Columbia, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Henry Ford Health System, Detroit, Michigan, United States
- Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
- University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
- Duke Neurological Disorders Clinic, Durham, North Carolina, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06558279 on ClinicalTrials.govOther trials for Adult-onset myasthenia gravis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06987539A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)Amgen
- RECRUITINGPHASE2NCT07501702A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisVertex Pharmaceuticals Incorporated
- RECRUITINGPHASE1NCT07526493Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.Tongji Hospital
- RECRUITINGNANCT07413835Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)The Affiliated Hospital of Xuzhou Medical University
- RECRUITINGPHASE1, PHASE2NCT07089121Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune DisordersCartesian Therapeutics
- RECRUITINGPHASE1NCT07304154A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic DiseasesKite, A Gilead Company
- RECRUITINGPHASE4NCT07221838A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With RavulizumabAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE1, PHASE2NCT07250750A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia GravisImmunAbs Inc.